Michael Cheah

Venture Advisor

Dr. Michael Cheah has nearly 30 years experience in senior management consulting in the medical and health industry and has experience in multiple joint ventures for pharmaceutical companies. Cheah has served as the president of Xi’an Janssen Pharmaceutical Company, Johnson and Johnson’s largest company in China. Prior to that, Michael Cheah was the CEO of Sino-US Tianjin Smithkline Pharmaceutical Co. Sino-US Smithkline is the largest subsidiary of GlaxoSmithKline in China and is one of the world’s leading vaccine manufacturers. Dr. Cheah received his bachelors and MBA at the University of New South Wales in Australia. He also received his Doctorates of Business Administration from the University of Liverpool in the UK.

Guanxi

Chinese Pharmaceutical Companies

Drug Manufacturing

Management Consulting

Biotechnology

Joint Ventures

Home          Press          Media          Contact

© 2020 by Summer Atlantic Capital